IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer
This work demonstrated a novel mechanism involving the IMP2-IPO4/SLC7A11 pathway as a promising treatment target for cisplatin-resistant bladder cancer.
Authors
- Yi‐Lin Yan (ORCID: https://orcid.org/0000-0002-5215-8702)
- Bing Shen (ORCID: https://orcid.org/0000-0002-0952-2257)
- Chenkai Yang (ORCID: https://orcid.org/0000-0001-7961-9495)
- Shujie Xia (ORCID: https://orcid.org/0000-0002-2293-3157)
- Zhengnan Huang (ORCID: https://orcid.org/0000-0001-8081-8619)
- Zhen Zhu (ORCID: https://orcid.org/0000-0002-7040-9288)
- Junfeng Jiang (ORCID: https://orcid.org/0000-0001-6065-1591)
- Xiangqian Cao (ORCID: https://orcid.org/0009-0004-9768-007X)
- Yang Wang (ORCID: https://orcid.org/0000-0002-9694-2267)
Institutions
- Tongji University (CN)
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Shanghai Tenth People's Hospital (CN)
- Shanghai First People's Hospital (CN)
- Jiangsu Province Hospital (CN)
- Tongji Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1186/s12935-024-03570-4
- Citations
- 7
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.64
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Shanghai Rising-Star Program